Xencor (NASDAQ:XNCR) Receives "Sell (D-)" Rating from Weiss Ratings

Key Points

• Xencor's stock has been given a "sell (D-)" rating by Weiss Ratings, while other analysts have varying perspectives with several maintaining a buy or outperform rating.
• The company's stock is currently trading at $11.68, reflecting a 16.3% decline during midday trading.
• Xencor reported quarterly earnings with a revenue increase of 82.4% year-over-year, reporting $43.61 million in revenue despite a net loss.

Xencor (NASDAQ:XNCR - Get Free Report)'s stock had its "sell (d-)" rating reiterated by equities researchers at Weiss Ratings in a note issued to investors on Tuesday,Weiss Ratings reports.

XNCR has been the topic of several other research reports. Wedbush reiterated an "outperform" rating and set a $26.00 price objective on shares of Xencor in a report on Tuesday, September 2nd. Barclays assumed coverage on shares of Xencor in a research report on Wednesday, September 17th. They set an "underweight" rating and a $6.00 target price for the company. Royal Bank Of Canada reduced their price objective on shares of Xencor from $32.00 to $15.00 and set an "outperform" rating for the company in a research report on Thursday, August 21st. Bank of America downgraded shares of Xencor from a "buy" rating to a "neutral" rating and reduced their price objective for the stock from $23.00 to $12.00 in a research report on Wednesday, September 3rd. Finally, Wells Fargo & Company reduced their target price on shares of Xencor from $33.00 to $27.00 and set an "overweight" rating for the company in a research report on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $24.22.

Xencor Trading Down 16.3%

XNCR stock traded down $2.28 during midday trading on Tuesday, hitting $11.68. The stock had a trading volume of 1,442,874 shares, compared to its average volume of 821,513. The firm has a market cap of $832.95 million, a P/E ratio of -4.86 and a beta of 0.96. Xencor has a 1-year low of $6.92 and a 1-year high of $27.24. The business has a fifty day moving average price of $9.31 and a two-hundred day moving average price of $9.04.

Xencor (NASDAQ:XNCR - Get Free Report) last released its earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $0.37. Xencor had a negative net margin of 121.52% and a negative return on equity of 25.75%. The business had revenue of $43.61 million for the quarter, compared to analyst estimates of $22.59 million. During the same quarter in the previous year, the business earned ($1.07) earnings per share. Xencor's revenue for the quarter was up 82.4% on a year-over-year basis. On average, equities analysts anticipate that Xencor will post -3.68 EPS for the current year.

Institutional Trading of Xencor

Several institutional investors and hedge funds have recently bought and sold shares of XNCR. GAMMA Investing LLC lifted its stake in Xencor by 348.5% in the 1st quarter. GAMMA Investing LLC now owns 9,629 shares of the biopharmaceutical company's stock worth $102,000 after purchasing an additional 7,482 shares in the last quarter. Exchange Traded Concepts LLC lifted its stake in Xencor by 23.9% in the 1st quarter. Exchange Traded Concepts LLC now owns 9,814 shares of the biopharmaceutical company's stock worth $104,000 after purchasing an additional 1,896 shares in the last quarter. Diversified Trust Co purchased a new stake in Xencor in the 1st quarter worth approximately $172,000. New York State Teachers Retirement System lifted its stake in Xencor by 2.1% in the 1st quarter. New York State Teachers Retirement System now owns 59,326 shares of the biopharmaceutical company's stock worth $631,000 after purchasing an additional 1,200 shares in the last quarter. Finally, Principal Financial Group Inc. lifted its stake in Xencor by 2.5% in the 1st quarter. Principal Financial Group Inc. now owns 348,726 shares of the biopharmaceutical company's stock worth $3,710,000 after purchasing an additional 8,581 shares in the last quarter.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.